Source comparison
TB-500 Studied Meniscus Injury: Research vs Clinical Application Comparison
Preclinical animal models (rat, rabbit, equine) 2–5mg twice weekly for 4–6 weeks Histological collagen organisation, VEGF expression, inflammatory marker reduction Subcutaneous or intramuscular injection near injury site Measurable tissue regeneration at 4–6 w
This comparison does not assign a generated winner or score.
- Preclinical animal models (rat, rabbit, equine)
- 2–5mg twice weekly for 4–6 weeks
- Histological collagen organisation, VEGF expression, inflammatory marker reduction
- Subcutaneous or intramuscular injection near injury site
- Measurable tissue regeneration at 4–6 weeks; structural integrity confirmed at 8–12 weeks
- Animal data shows consistent regenerative benefit but cannot be directly extrapolated to human meniscus healing timelines without Phase III human trials
- Human case reports (off-label use)
- 2–3mg twice weekly for 6 weeks, followed by 1–2mg weekly maintenance
- Self-reported pain reduction, functional mobility improvement
- Subcutaneous injection (typically abdominal or thigh)
- Subjective improvement reported within 2–4 weeks; no standardised imaging follow-up in most reports
- Anecdotal evidence suggests clinical benefit but lacks controlled comparison group. Placebo effect and concurrent physical therapy confound interpretation
- In vitro cell culture studies
- 1–10 µg/mL concentration in culture medium
- Cell migration rate, MMP expression, actin dynamics
- Direct medium supplementation
- Migration increase observed within 12–24 hours; sustained effect for 48–72 hours
- Demonstrates receptor-level mechanism but oversimplifies the complex in vivo environment where immune cells, mechanical load, and vascular access all influence outcomes